IVD INTERNAL QUALITY CONTROLS WILL EASE CLIA QC REQUIREMENTS UNDER REVISED REGULATION; QC PHASE-IN FOR MODERATE COMPLEXITY TESTS TO BE EXTENDED
This article was originally published in The Gray Sheet
Laboratories using test systems with advanced internal quality control capabilities will face less stringent QC requirements under upcoming revisions to regulations on the Clinical Laboratory Improvement Amendments of 1988. The Centers for Disease Control and Prevention is revising CLIA QC rules to replace the now-defunct plan for government validation of manufacturers' labeling as a means for laboratories to comply with the rules.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.